A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)

Cancer: Solid Tumors Clinical Trial

Official title:
A Phase Ib Dose Escalation Study of MK-4827 in Combination With Carboplatin, Carboplatin/Paclitaxel and Carboplatin/Liposomal Doxorubicin in Patients With Advanced Solid Tumors

Status Terminated

Clinical Trial Summary

This study will find the dose limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended Phase 2 dose (RPTD) of MK4827 when administered in combination with standard doses of carboplatin, or carboplatin/paclitaxel, or carboplatin/liposomal doxorubicin in the treatment of advanced solid cancers in adults.

Clinical Trial Description

The decision to discontinue new enrollment is not related to any concerns about the safety profile of the product. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Cancer: Solid Tumors

Clinical Trial Details

NCT number	NCT01110603
Study type	Interventional
Source	Tesaro, Inc.
Contact
Status	Terminated
Phase	Phase 1
Start date	July 2010
Completion date	July 2011

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00280397` - An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors	Phase 1